solventum

3M[™] Tegaderm[™] **Dressing** Portfolio

A family of reliable IV dressings

For over 40 years, we have collaborated with healthcare professionals around the world to develop products that simplify and help improve patient care practices.

We continue to develop products that help protect patients and prevent the risks of costly complications.

Aligns to standards and guidelines

Tegaderm Dressings not only help protect your patients, but they also meet the guidelines below for care and maintenance of vascular access devices.

U.S. Food & Drug Administration (FDA)

3M[™] Tegaderm[™] CHG Chlorhexidine Gluconate I.V. Securement Dressing is the only transparent dressing cleared and proven to reduce catheter-related bloodstream infection (CRBSI).¹

Centers for Disease Control and Prevention (CDC)

For patients aged 18 years and older: Chlorhexidine-impregnated dressings with an FDA-cleared label that specifies a clinical indication for CRBSI or catheter-associated bloodstream infection (CABSI) are recommended to protect the insertion site of short-term, non-tunneled central venous catheters (CVCs) (Category IA).²


Infusion Nurses Society (INS)

Consider the use of chlorhexidine-impregnated dressings for patients with an epidural access device. A significant reduction in epidural skin colonization and catheter tip colonization has been demonstrated with their use. Std. 53, S198 (Level I)³

Use chlorhexidine gluconate (CHG)-containing dressings to prevent central line-associated bloodstream infections (CLABSIs) in patients greater than two months of age with short-term central venous access devices (CVADs), unless contraindicated (e.g., sensitivity or allergy to CHG), including patients with oncohematological disease (see Standard 39, Vascular Access Device Post-Insertion Care). Std. 47, S171 (Level I)³

Assess the vascular access device (VAD) site and surrounding area by palpation and inspection, including catheter pathway, for integrity of skin, dressing, and securement device. Std. 39, pg. S132 (Level IV)³

Inspired by you: A timeline of innovation




1. U.S. Food and Drug Administration, Department of Health & Human Services, 3M Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressing 510(k) K153410 Approval Letter, by David Krause, OMB No. 0910-0120, Silver Spring, MD: 2017, https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153410.pdf (accessed June 18, 2020).

2. Naomi P. O'Grady et al. "Guidelines for the Prevention of Intravascular Catheter-related Infections." Clin Infect Dis 52, no. 9 (May 2011): e162-e193. https://doi.org/10.1093/cid/cir257. 3. Barbara Nickel et al. "Infusion Therapy Standards of Practice, 9th Edition." J Infus Nurs 47, no 1S Suppl 1 (Jan-Feb 2024): S1-S285. https://www.doi.org/10.1097/NAN.00000000000532. PMID: 38211609.









Important Safety Information for Tegaderm CHG I.V. Securement Dressings and Tegaderm CHG Gel Pad. Do not use Tegaderm CHG I.V. Securement Dressings or Tegaderm CHG Gel Pad on premature infants or infants younger than two months of age. Use of these products on premature infants may result in hypersensitivity reactions or necrosis of the skin. The safety and effectiveness of Tegaderm CHG I.V. Securement Dressings and Tegaderm CHG Gel Pad has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). Rx Only.

© Solventum 2024. All Rights Reserved. Solventum and the S logo are trademarks of Solventum or its affiliates. 3M and the 3M logo are trademarks of 3M. Other trademarks are the property of their respective owners. 70-2013-1250-0 Solventum 2510 Conway Ave E Maplewood, MN 55144 USA 1-800-228-3957 Solventum.com

